Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical consequences of hyperlipidaemia.

G R Thompson1

  • 1MRC Lipoprotein Team, Hammersmith Hospital, London, UK.

Journal of Inherited Metabolic Disease
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections.

Infectious diseases and therapy·2022
Same author

Coccidioidomycosis in llamas and alpacas diagnosed at the University of California, Davis (1990-2016).

Medical mycology·2020
Same author

Ibrexafungerp: A novel oral glucan synthase inhibitor.

Medical mycology·2019
Same author

A microbiome assessment of medical marijuana.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

The Nobel dilemma: to reward scientific discovery or benefit to mankind?

QJM : monthly journal of the Association of Physicians·2015
Same author

Dyslipidaemia and the military patient.

Journal of the Royal Army Medical Corps·2015
Same journal

Biallelic Loss-Of-Function Variant in ATP5ME Is Associated With Severe and Early Onset Oxidative Phosphorylation Deficiency.

Journal of inherited metabolic disease·2026
Same journal

Beyond Upper Airway Involvement: Evidence of Intrinsic Lung Disease in a Mouse Model of Mucopolysaccharidosis I.

Journal of inherited metabolic disease·2026
Same journal

Immune Dysregulation in Branched Chain Organic Acidemias.

Journal of inherited metabolic disease·2026
Same journal

Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.

Journal of inherited metabolic disease·2026
Same journal

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same journal

Mapping the Severity of Phenylalanine Hydroxylase Deficiency.

Journal of inherited metabolic disease·2026
See all related articles

Hyperlipidaemia, often genetic, causes high cholesterol or triglycerides. Recognizing and treating it, especially familial hypercholesterolaemia, can prevent severe issues like pancreatitis and heart disease.

Area of Science:

  • Clinical Medicine
  • Genetics
  • Cardiology

Background:

  • Hyperlipidaemia is a prevalent clinical condition with a significant genetic component.
  • Severe hypertriglyceridaemia presents with eruptive xanthomata and acute pancreatitis.
  • Hypercholesterolaemia, particularly familial hypercholesterolaemia, is linked to premature coronary heart disease and tendon xanthomata.

Purpose of the Study:

  • To highlight the clinical significance of hyperlipidaemia.
  • To emphasize the genetic underpinnings of lipid disorders.
  • To underscore the importance of early recognition and improved treatment for managing hyperlipidaemia.

Main Methods:

  • Clinical observation and case studies.
  • Genetic analysis for familial hypercholesterolaemia.

Related Experiment Videos

  • Review of diagnostic criteria and treatment advancements.

    • Main Results:

    • Identification of distinct clinical features for hypertriglyceridaemia and hypercholesterolaemia.
    • Association of familial hypercholesterolaemia with specific physical signs like tendon xanthomata.
    • Demonstration of the link between lipid levels and cardiovascular risk.

    Conclusions:

    • Improved recognition of hyperlipidaemia is crucial for patient outcomes.
    • Advances in treatment offer potential to mitigate severe consequences.
    • Effective management can reduce the incidence of disabling and fatal outcomes associated with hyperlipidaemia.